Anzeige
Mehr »
Login
Donnerstag, 28.01.2021 Börsentäglich über 12.000 News von 653 internationalen Medien
East Africa Metals - Beginn der Goldförderung - JETZT! Strong Buy!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 ISIN: JP3463000004 Ticker-Symbol: TKD 
Tradegate
27.01.21
17:54 Uhr
29,995 Euro
-0,355
-1,17 %
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
29,33529,81527.01.
29,00030,00027.01.
Dow Jones News
3.163 Leser
Artikel bewerten:
(2)

DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast 
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of 
Consolidated Financials for FY2020 (IFRS) 
 
31-Jul-2020 / 08:00 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation 
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
*Notice of the Revised Forecast of Consolidated Financials for FY2020 
(IFRS)* 
 
*Osaka, Japan, July 31, 2020 - *Takeda Pharmaceutical Company Limited 
(TSE:4502/NYSE:TAK [1]) ("Takeda") announced today, the revised forecast of 
the full year consolidated financials for the fiscal year ending March 31, 
2021, as below. 
 
*1. *Revised Forecast for Full Year Consolidated Financials for the Fiscal 
Year Ending March 31, 2021 
 
(millions of yen) 
 
            Revenue   Core    Operating Profit  Net   Basic Core 
                    Operating  profit   before profit earni EPS 
                     Profit             income attrib  ngs 
                                        taxes  utable  per 
                                                 to   share 
                                               owners 
                                                 of 
                                                the 
                                               Compan 
                                                 y 
Previous    3,250,0   984,000   355,000 200,00 60,000 38.52  420 
Forecast         00                          0          yen  yen 
(A)* 
Revised     3,250,0   984,000   395,000 230,00 92,000 58.91  420 
Forecast         00                          0          yen  yen 
(B) 
Discrepancy       ?         ?   +40,000 +10,00 +32,00     ?    ? 
(B-A)                                        0      0 
Change %          ?         ?    +11.3% +15.0% +53.3%     ?    ? 
 
* Announced on May 13, 2020. 
 
2. Reasons for Revision 
 
The revenue forecast has not been changed at 3,250.0 billion JPY. 
 
The Operating Profit forecast has been increased by 40.0 billion JPY, or 
11.3%, to 395.0 billion JPY. This reflects a net positive effect of one-time 
items recognized during the first quarter of FY2020: an approximately 60.0 
billion JPY profit due to an update to previously recognized liabilities for 
SHP647 to reflect a change in expected future costs, such as program 
termination costs, as a result of the European Commission's decision to 
release Takeda from the obligation to divest SHP647; and an approximately 
20.0 billion JPY loss due to the remeasurement of contingent consideration 
assets at fair value as a result of Novartis' withdrawal of the Marketing 
Authorisation Application in Europe for XIIDRA. 
 
The profit before tax forecast has been increased by 30.0 billion JPY, or 
15.0%, to 230.0 billion JPY. This reflects an approximately 10.0 billion JPY 
loss of associates accounted for using the equity method recognized during 
the first quarter of FY2020, mainly due to an impairment charge on certain 
assets recognized by Teva Takeda Pharma Ltd. 
 
The forecast for net profit for the period attributable to owners of the 
Company has been increased by 32.0 billion JPY, or 53.3%, to 92.0 billion 
JPY, due to the factors explained above and associated tax benefits. 
 
The forecasts for Core Operating Profit and Core EPS remain unchanged as the 
factors explained above are unusual, non-recurring items and unrelated to 
our ongoing operations. 
 
3. Management Guidance 
 
There are no changes in the Management Guidance. 
 
                    Previous Guidance       Revised Guidance 
                     (May 13, 2020)          (July 31, 2020) 
Underlying       Low-single-digit growth Low-single-digit growth 
Revenue Growth 
Underlying Core     High-single-digit       High-single-digit 
Operating Profit         growth                  growth 
Growth 
Underlying Core         Low-30s%                Low-30s% 
Operating Profit 
Margin 
Underlying Core      Low-teen growth         Low-teen growth 
EPS Growth 
 
*About Takeda Pharmaceutical Company Limited* 
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK [1]) is a global, 
values-based, R&D-driven biopharmaceutical leader headquartered in Japan, 
committed to bringing Better Health and a Brighter Future to patients by 
translating science into highly-innovative medicines. Takeda focuses its R&D 
efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, 
and Gastroenterology (GI). We also make targeted R&D investments in 
Plasma-Derived Therapies and Vaccines. We are focusing on developing highly 
innovative medicines that contribute to making a difference in people's 
lives by advancing the frontier of new treatment options and leveraging our 
enhanced collaborative R&D engine and capabilities to create a robust, 
modality-diverse pipeline. Our employees are committed to improving quality 
of life for patients and to working with our partners in health care in 
approximately 80 countries. 
For more information, visit https://www.takeda.com [2]. 
 
*Contacts:* 
 
*Investor Relations*              *Media Relations* 
Takashi Okubo, +81-(0)3-3278-2306 Kazumi Kobayashi, +81 
takeda.ir.contact@takeda.com      (0)3-3278-2095 
                                  kazumi.kobayashi@takeda.com 
 
*Important Notice* 
For the purposes of this notice, "press release" means this document, any 
oral presentation, any question and answer session and any written or oral 
material discussed or distributed by Takeda Pharmaceutical Company Limited 
("Takeda") regarding this release. This press release (including any oral 
briefing and any question-and-answer in connection with it) is not intended 
to, and does not constitute, represent or form part of any offer, invitation 
or solicitation of any offer to purchase, otherwise acquire, subscribe for, 
exchange, sell or otherwise dispose of, any securities or the solicitation 
of any vote or approval in any jurisdiction. No shares or other securities 
are being offered to the public by means of this press release. No offering 
of securities shall be made in the United States except pursuant to 
registration under the U.S. Securities Act of 1933, as amended, or an 
exemption therefrom. This press release is being given (together with any 
further information which may be provided to the recipient) on the condition 
that it is for use by the recipient for information purposes only (and not 
for the evaluation of any investment, acquisition, disposal or any other 
transaction). Any failure to comply with these restrictions may constitute a 
violation of applicable securities laws. 
The companies in which Takeda directly and indirectly owns investments are 
separate entities. In this press release, "Takeda" is sometimes used for 
convenience where references are made to Takeda and its subsidiaries in 
general. Likewise, the words "we", "us" and "our" are also used to refer to 
subsidiaries in general or to those who work for them. These expressions are 
also used where no useful purpose is served by identifying the particular 
company or companies. 
 
*Forward-Looking Statements* 
This press release and any materials distributed in connection with this 
press release may contain forward-looking statements, beliefs or opinions 
regarding Takeda's future business, future position and results of 
operations, including estimates, forecasts, targets and plans for Takeda. 
Without limitation, forward-looking statements often include words such as 
"targets", "plans", "believes", "hopes", "continues", "expects", "aims", 
"intends", "ensures", "will", "may", "should", "would", "could" 
"anticipates", "estimates", "projects" or similar expressions or the 
negative thereof. These forward-looking statements are based on assumptions 
about many important factors, including the following, which could cause 
actual results to differ materially from those expressed or implied by the 
forward-looking statements: the economic circumstances surrounding Takeda's 
global business, including general economic conditions in Japan and the 
United States; competitive pressures and developments; changes to applicable 
laws and regulations; the success of or failure of product development 
programs; decisions of regulatory authorities and the timing thereof; 
fluctuations in interest and currency exchange rates; claims or concerns 
regarding the safety or efficacy of marketed products or product candidates; 
the impact of health crises, like the novel coronavirus pandemic, on Takeda 
and its customers and suppliers, including foreign governments in countries 
in which Takeda operates, or on other facets of its business; the timing and 
impact of post-merger integration efforts with acquired companies; the 
ability to divest assets that are not core to Takeda's operations and the 
timing of any such divestment(s); and other factors identified in Takeda's 
most recent Annual Report on Form 20-F and Takeda's other reports filed with 
the U.S. Securities and Exchange Commission, available on Takeda's website 
at: 
https://www.takeda.com/investors/reports/sec-filings/ [3] or at www.sec.gov 
[4]. Takeda does not undertake to update any of the forward-looking 
statements contained in this press release or any other forward-looking 
statements it may make, except as required by law or stock exchange rule. 
Past performance is not an indicator of future results and the results or 
statements of Takeda in this press release may not be indicative of, and are 
not an estimate, forecast, guarantee or projection of Takeda's future 
results. 
 
### 
 
31-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory 
Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     Takeda Pharmaceutical Company Limited 
             1-1, Nihonbashi-Honcho 2-Chrome, Chuo-ku 
             103-8668 Tokyo 
             Japan 
Phone:       +81-3-3278-2039 
E-mail:      hisashi.tokinoya@takeda.com 
ISIN:        JP3463000004, XS1843449981, XS1843450138, XS1843449049, 
             XS1843449809, XS1843449122, XS1843449395, 
WKN:         853849 
Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, 
             Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID: 1106067 
 
End of Announcement DGAP News Service 
 
1106067 31-Jul-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=069766b3e233ea94c307c400b0d311ad&application_id=1106067&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=014ede1f116f53683292fb081f8c28c5&application_id=1106067&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=661befb44ac9648638f94a535445077e&application_id=1106067&site_id=vwd&application_name=news 
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=20e944ef12a652f477b781c7ef4d6f68&application_id=1106067&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

July 31, 2020 02:00 ET (06:00 GMT)

TAKEDA PHARMACEUTICAL-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2020 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.